论文部分内容阅读
2003年1月。中国证监会调查组进驻烟台发展(600766)立案调查。具体原因迄今未明。这家上市近7年的公司历经多次重组,至今已三易其主,而其现任大股东深圳万策入主手法在国内资本市场上十分罕见:先由母公司万基医药掩护达成收购协议,后由子公司万策出面接手,继而在收购上市公司后进一步收购了上市公司母公司鲁信国际。在支付了高达2.27亿元现金的双重成本之后,令人疑惑的是,我们并未看到烟台发展有任何实质性重组。公司业绩也继续不断下滑,目前面临戴帽危险。从这点看,万策收购烟台发展的独特技巧背后所隐藏的真实动机,我们还需拭目以待◇文/吕爱兵
January 2003 China Securities Regulatory Commission investigation team stationed in Yantai Development (600766) investigation. The specific reason is unknown so far. The listing of nearly seven years of the company after repeated restructuring, has so far three easy to its owner, and its current major shareholder Shenzhen Wanzhao approach is very rare in the domestic capital markets: the first by the parent company Mankiw medicine cover reached an acquisition agreement, After taking over by the subsidiary Wan policy, and then the acquisition of listed companies further acquisition of the parent company of listed companies Lu Shin International. After paying the double cost of up to 227 million yuan in cash, it is puzzling that we did not see any substantial restructuring of Yantai’s development. Company performance also continued to decline, currently facing the danger of wearing a hat. From this point of view, Wan strategy acquisition of the unique motivation behind the development of Yantai hidden true motivation, we still have to wait and see ◇ text / Lu Aibing